2023-05-17 07:01:00
[Welfare News]Dongkuk Pharmaceutical (CEO Song Joon-ho) and Genencell (CEO Oh Young-cheol) jointly developed natural material ‘malt and gujeolcho complex (ingredient name: Freemencia)’ developed by the Ministry of Food and Drug Safety for women’s menstrual Approval for individually recognized functional ingredients related to the improvement of pre-menstrual syndrome (PMS) was recently obtained (Accreditation No. 2023-12).
The two companies succeeded in developing this raw material through joint research by investing regarding 3 billion won for regarding six years from 2017. Currently, there is only one functional ingredient for symptom improvement, which is a notification type, ‘fat containing gamma linolenic acid’. For the first time, individually approved raw materials were recognized for their functionality with the content that ‘it can help improve uncomfortable conditions caused by premenstrual changes’.
Through preclinical tests and human application tests, ‘Freemencia’ has been proven to normalize secretion of prolactin hormone (milk hormone) and inhibit activity of estrogen (female hormone) receptors due to dopamine receptor activation. Through this, it was confirmed that the symptom relief of premenstrual syndrome, the protection of pituitary cells, and the improvement of intrauterine inflammation were confirmed.
An official from Dongkuk Pharmaceutical said, “Since female premenstrual syndrome requires long-term management, consumer demand for health functional foods with excellent efficacy and fewer side effects is continuously increasing.” It is expected to be well received by the market,” he said.
Dongkuk Pharmaceutical is currently developing a product with a customized formulation, and has selected teenagers as the main target and working women in their 20s as the sub target. In December, the company plans to launch and sell products by programing them as women’s care for each age group on the online official mall.
Meanwhile, Genencell has completed registration of a total of three domestic patents for this invention and has applied for patents in nine overseas regions including the US, Europe, Australia and Japan.
1684309129
#Dongkook #PharmGenencell #Acquire #Individually #Recognized #Raw #Material #Improving #Premenstrual #Syndrome #Welfare #Shinbo
